{"id":6400,"date":"2012-06-24T12:46:00","date_gmt":"2012-06-24T12:46:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/here-come-pharma-wikipedians\/"},"modified":"2019-02-21T01:19:22","modified_gmt":"2019-02-21T01:19:22","slug":"here-come-pharma-wikipedians","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/here-come-pharma-wikipedians\/","title":{"rendered":"Here Come the Pharma Wikipedians!"},"content":{"rendered":"
\n<\/a><\/div>\n

Should pharmaceutical companies appoint employees as Wikipedia “spokespeople” to perform all edits to Wikipedia articles on behalf of the company? That is the opinion of Bertalan Mesk\u00f3, MD, founder and managing director of Webicina.com, who invited pharmaceutical companies to “employ a Wikipedia editor if you want to make sure only evidence-based information is included in entries about your own products” (find his letter here<\/a>).<\/p>\n

Recall that PhRMA — in comments submitted to the FDA (see “Accountability for Pharma Content on Social Media Sites<\/a>“) — suggested that manufacturers would welcome correcting misinformation about their products posted to sites like Wikipedia if these corrections were not subject to FDA regulation.<\/p>\n

“FDA,” said PhRMA, “should confirm formally that, while it is not possible for manufacturers to monitor or correct all inaccurate information about their products on the Internet, such corrections by manufacturers in response to inaccurate postings will not be considered promotional labeling. FDA’s adoption of such a policy would thereby allow manufacturers to correct inaccurate information about their medicines on the Internet or social media (e.g., Wikipedia, Sidewiki, blogs, or other websites) if they should become aware of such information.”<\/p>\n

PODCAST<\/b>
\nPharma does not have a stellar record when it comes to editing Wikipedia articles. See, for example, “Simply Irresistible: Abbott Tampering with Wikipedia Entries<\/a>” and “Web 2.0 Pharma Marketing Tricks for Dummies<\/a>.” So it’s no surprise that this raises a number of interesting issues that were hotly debated during a recent #hcsmeu Twitter chat. That discussion will be continued in a Pharma Marketing Talk podcast on Tuesday, July 17, 2012. You are invited to listen or call in with your opinions. For more information, go here<\/a>.<\/p>\n

SURVEY<\/b>
\nMeanwhile, I invite you to respond to the short survey below, which asks your opinion regarding the issues. Specifically, the survey asks whether or not you agree to the following statements:<\/p>\n